Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality and has become the third leading cause of death in the world.[@CIT0001],[@CIT0002] Acute exacerbations are an important event in COPD with many therapies directed at their prevention[@CIT0003] and these exacerbations impact significantly on patient-related outcomes.[@CIT0004] An US Food and Drug Administration (FDA) briefing document on the benefits and risks of systemic fluoroquinolones, based on review of 15 placebo-controlled trials of anti-bacterial treatment of acute exacerbations of COPD (AECOPD), found that evidence of benefit was inconsistent, especially for mild exacerbations. The benefit was more evident for severe exacerbations requiring hospitalisation.[@CIT0005] Similar results have been reported by the Cochrane Collaboration which found a strong benefit in intensive care unit patients, but low-quality evidence and modest benefit overall.[@CIT0006] Guidelines suggest treating AECOPD with antibiotics for exacerbations of at least moderate disease severity, as indicated by at least two of increased sputum volume, purulence, or worsening dyspnea.[@CIT0001],[@CIT0007],[@CIT0008] First-line antibiotics suggested include macrolides, second- or third-generation cephalosporins, trimethoprim-sulfamethoxazole, or doxycycline. Respiratory fluoroquinolones are reserved for patients with severe COPD, significant cardiac co-morbidity or frequent exacerbations.[@CIT0001] The fluoroquinolones appear effective in treating COPD exacerbations even with short courses.[@CIT0009] There was concern early that they might be overused with increasing microbial resistance.[@CIT0010] Concern as to overuse of fluoroquinolones increased in pertinence with the report of rare but potentially disabling adverse effects such as Achilles tendonitis with rupture,[@CIT0011] aortic aneurysm,[@CIT0012] retinal detachment[@CIT0013] and peripheral neuropathy.[@CIT0014] Widespread use of fluoroquinolones has continued despite these concerns.[@CIT0005] For example, fluoroquinolones were the second most widely prescribed class of antibiotics in subjects over the age of 65 years in Ontario, Canada from 2006 to 2015.[@CIT0015] Serious adverse effects continue to be reported leading to advisories from Health Canada[@CIT0016] and the FDA,[@CIT0017] most recently for aortic aneurysms. The National Institute for Health and Care Excellence (NICE) from the UK has also recently suggested a more restricted use of antibiotics in AECOPD.[@CIT0018] We wished to examine, using administrative health care databases in Canada, whether the use of fluoroquinolones in patients with uncomplicated acute exacerbations of COPD is of benefit, thus justifying their use in this situation.

Materials And Methods {#S0002}
=====================

Data Sources {#S0002-S2001}
------------

We conducted a retrospective cohort study to compare the effectiveness of fluoroquinolone versus non-fluoroquinolone antibiotics in the treatment of uncomplicated acute exacerbations of COPD. The study was conducted under the auspices of the Canadian Network for Observational Drug Effect Studies (CNODES), a distributed network of investigators and linked databases across the majority of Canadian provinces.[@CIT0019],[@CIT0020] In each province of the CNODES network, the universal healthcare system provides validated, population-wide, de-identified healthcare utilization data, linkable at the patient level using encoded healthcare numbers. Dispensed drug prescriptions are available for almost all subjects 65 years or older (\>97% for most provinces; Nova Scotia 69%). A common protocol was implemented separately within each of the provinces and aggregate results were pooled across provinces. We used these administrative health databases from the provinces of Alberta, British Columbia, Manitoba, Nova Scotia, Ontario and Saskatchewan.

Inclusion/Exclusion Criteria {#S0002-S2002}
----------------------------

Subjects were included in the cohort if they had a physician or nurse practitioner visit with a diagnostic code for COPD (ICD-9 490.x, 491.x, 492.x, 496.x and ICD-10 J40.x--J44.x), were at least 66 years of age, and had health care coverage for a minimum of 365 days before the visit for COPD. COPD visits with a dispensing of an antibiotic within 5 days were considered to represent an AECOPD. To limit the cohort to uncomplicated acute exacerbations of COPD, we excluded subjects with a medical outpatient visit for COPD, a hospitalisation for any cause, or use of an antibiotic or oral corticosteroid in the prior 90 days. These exclusions, within the limitations of the administrative data, are consistent with guideline definitions of uncomplicated acute exacerbations of COPD.[@CIT0007] We also excluded subjects with ischemic heart disease or heart failure in the prior year. Subjects were also required to have at least 35 days of information after the AECOPD.

Outcomes {#S0002-S2003}
--------

Outcomes examined were repeat ambulatory care visits for COPD, hospitalisation with COPD as a diagnostic code in any position, or subsequent antibiotic prescriptions, all within 30 days of the antibiotic dispensing date used to identify an AECOPD. The study period was variable between databases but information was collected between January 1st, 2005 and March 31st, 2017. The study protocol was approved by the institutional review boards at all participating sites.

For each outcome, marginal adjusted odds ratios (OR) and their 95% confidence intervals (CI) were estimated using logistic regression adjusting for age and calendar year. High-dimensional propensity scores were computed to identify and control for confounders and inverse probability of treatment weights (IPTW) were used to ensure comparable treatment groups.[@CIT0021],[@CIT0022] Aggregate results within each province were then pooled across provinces, weighted by the inverse of the standard error of the estimate, using a random effects model. Heterogeneity across provinces was assessed using the I^2^ statistic. As sensitivity analyses, individual patients were considered only once with the AECOPD event chosen at random, or the observation period after the antibiotic was dispensed was increased from 30 days to 60 days.

Results {#S0003}
=======

We identified 268,886 AECOPD events among 203,642 unique individuals ([Figure 1](#F0001){ref-type="fig"}). Overall fluoroquinolones, mostly levofloxacin and moxifloxacin, were used 20.8% of the time but the use varied from 8% to 32% of AECOPD, depending on the province. The most commonly dispensed non-fluoroquinolone antibiotics were clarithromycin, azithromycin, amoxicillin, or doxycycline ([Table 1](#T0001){ref-type="table"}). Higher crude outcome event rates for repeat ambulatory care visits, hospitalisations, and subsequent antibiotic prescriptions were observed among patients treated with a fluoroquinolone compared to those treated with other antibiotics ([Table 2](#T0002){ref-type="table"}). Propensity weighted analyses are provided by Forest plots in [Figures 2](#F0002){ref-type="fig"}--[4](#F0004){ref-type="fig"}. [Figure 2](#F0002){ref-type="fig"} provides the risk of a repeat ambulatory care visit. Overall this is increased among patients dispensed a fluoroquinolone (OR 1.32, 95% CI 1.27--1.36). [Figure 3](#F0003){ref-type="fig"} shows that the risk of hospitalisation within 30 days of being dispensed a fluoroquinolone is higher than for subjects prescribed other antibiotics (OR 1.52, 95% CI 1.33--1.74). There was no difference in subsequent antibiotic prescriptions (OR 1.00, 95% CI 0.94--1.07) ([Figure 4](#F0004){ref-type="fig"}). Results were very similar when considering only one AECOPD per individual or when extending the period of observation to 60 days after the antibiotic was dispensed (data not shown).Table 1Frequency Of Antibiotics Used For Initial Treatment Of Acute Exacerbations Of COPDAntibioticCountPercentClarithromycin54,29220.2%Azithromycin48,99218.2%Amoxicillin38,37614.3%Moxifloxacin27,82910.3%Doxycycline21,7498.1%Levofloxacin19,2547.2%Cefuroxime14,9715.6%Amoxicillin/Clavulanate10,3663.9%Ciprofloxacin80883.0%Cephalexin69752.6% Table 2Crude Outcome Event Rates (%) Among AECOPD Treated With A Fluoroquinolone Compared With Other AntibioticsProvinceRepeat Ambulatory Care Visit For AECOPDHospitalisation For AECOPDSubsequent Antibiotic DispensationFQOther ABFQOther ABFQOther ABAlberta24.517.73.251.7916.816.3British Columbia26.019.81.630.6516.816.1Manitoba23.815.92.050.9117.015.1Nova Scotia30.922.12.471.2217.715.1Ontario22.717.43.231.9816.716.7Saskatchewan27.317.24.431.3519.116.1[^1] Figure 1Flow chart for study cohort creation.**Note:** Patients were allowed to enter the cohort multiple times with a new AECOPD event.**Abbreviation:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease.Figure 2ORs (95% CI) for repeat ambulatory care visits associated with AECOPD initially treated with a fluoroquinolone compared with other antibiotics.**Abbreviations:** AB, antibiotics; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CI, confidence interval; FQ, fluoroquinolones; OR, odds ratio; SE, standard error; IV, inverse variance.Figure 3ORs (95% CI) for hospitalisations associated with AECOPD initially treated with a fluoroquinolone compared with other antibiotics.**Abbreviations:** AB, antibiotics; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CI, confidence interval; FQ, fluoroquinolones; OR, odds ratio; SE, standard error; IV, inverse variance.Figure 4ORs (95% CI) for subsequent antibiotic dispensations associated with AECOPD initially treated with a fluoroquinolone compared with other antibiotics.**Abbreviations:** AB, antibiotics; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CI, confidence interval; FQ, fluoroquinolones; OR, odds ratio; SE, standard error; IV, inverse variance.

Discussion {#S0004}
==========

We identified more than 200,000 subjects receiving an antibiotic concomitantly with a physician visit for COPD. We then compared short-term outcomes between subjects dispensed a fluoroquinolone versus another antibiotic after weighting on the propensity of receiving a fluoroquinolone rather than another antibiotic in an attempt to assure that subjects were comparable. Subjects dispensed a fluoroquinolone had more repeat physician visits and greater risk of hospitalisation within 30 days than those prescribed other antibiotics. The need for a subsequent antibiotic dispensing (within 30 or 60 days) was the same.

A recent FDA study examined utilization data but not outcomes using administrative and physician survey data.[@CIT0005] They found fluoroquinolones were associated with acute exacerbations of COPD 59.4% of the time in 2010 and 36.5% in 2014. While these values are higher than the 20.4% fluoroquinolone use found in this study, our approach targeted only uncomplicated exacerbations of COPD. A small study of primary care practice in the Netherlands evaluated the antibiotic prescribing of 1297 patients with exacerbations of COPD.[@CIT0023] Only 2% of the patients with single exacerbations received fluoroquinolone prescriptions. There was considerable variability across provinces in the rate of fluoroquinolone prescribing (8−32%) but even the lowest rate exceeds that seen in the Netherlands. This variability in the quality of prescribing for exacerbations across jurisdictions has been seen in other studies but the root causes of these differences require further investigation.[@CIT0024]

This population-based study of multiple cohorts has several strengths. The population and number of events are large permitting precise estimates in a real-world setting. Results were consistent in each of the provinces assuring that the results are generalisable. We used state-of-the-art methods to adjust for potential confounding. Of note, the results only apply to uncomplicated AECOPD, since we deliberately excluded those with recent exacerbations, hospitalisation, or significant cardiac co-morbidity as 2nd line antibiotics like fluoroquinolones may be justified in these patients.

This study has several limitations. First, the diagnosis of COPD is based on outpatient physician billing codes which may not be accurate since we do not have access to lung function test results. We assumed that a visit for COPD linked to a prescription for a respiratory antibiotic was indicative of a COPD exacerbation. This may, however, represent the dispensing of an antibiotic as part of an action plan for a future exacerbation. We do not think that this would be a common occurrence in the relatively uncomplicated patients with COPD we selected. Also, the antibiotic may have been prescribed for a concomitant pneumonia or other infection. We cannot be sure the weighting of patients by propensity scores is sufficient to eliminate confounding. We did not have important information such as lung function, use of home oxygen, smoking status, symptom scores or colonisation with more resistant bacteria such as *Pseudomonas*, that might have allowed us to render the treatment groups more comparable and help further ensure that more complicated exacerbations were excluded. Therefore, we do not feel that the poorer outcomes among those prescribed fluoroquinolones are causal but more likely reflect a more severe population.

In conclusion, treatment of apparently uncomplicated COPD exacerbations with fluoroquinolone versus non-fluoroquinolone antibiotics does not appear to be associated with improved outcomes in the following 30 days, including repeat ambulatory care visits, hospitalisation for COPD or repeat antibiotic prescriptions. These findings support current recommendations to limit the use of fluoroquinolones to more complicated patients with recurrent exacerbations or significant cardiac co-morbidity. Such judicious use is especially important given the rare but severe adverse effects associated with the use of fluoroquinolone antibiotics.
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